Matrix metalloproteinase-2 and epidermal growth factor are decreased in platelets of Alzheimer patients

Current Alzheimer Research

Volumn 9, Issue 8, 2012, Pages 982-989

  Hochstrasser, Tanja ^a   Ehrlich, Daniela ^a   Marksteiner, Josef ^b   Sperner Unterweger, Barbara ^a   Humpel, Christian ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Landeskrankenhaus Hall in Tirol ^*  (Austria)

Author keywords

Alzheimer; Biomarker; Diagnosis; EGF; MMP 2; Platelets

Indexed keywords

CD40 LIGAND; CELL ADHESION MOLECULE; CYTOKINE; EPIDERMAL GROWTH FACTOR; GELATINASE A; PLATELET DERIVED GROWTH FACTOR; SEROTONIN;

AGED; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; THROMBOCYTE COUNT;

AGED; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BLOOD PLATELETS; BLOTTING, WESTERN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 2;

EID: 84867754291     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512803251156     Document Type: Article

References (66)

1. Desai AK, Grossberg, GT. Diagnosis and treatment of Alzheimer's disease. Neurology 28: 34-39 (2005).
2. Fradinger EA, Bitan G. En route to early diagnosis of Alzheimer's disease-are we there yet? Trends Biotechnol. 23: 531-533 (2005).
3. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinalfluid of patients with Alzheimer disease JAMA 289: 2094-2103 (2003).
4. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2: 605-613 (2003).
5. Chen M, Inestrosa NC, Ross GS, Fernandez HL. Platelets are the primary source of amyloid beta-peptide in human blood. Biochem Biophys Res Commun 213: 96-103 (1995).
6. Stahl SM. Platelets as pharmacologic models for the receptors and biochemistry of monoaminergic neurons (Ch 13). The Platelets New York: Academic 308-40: 9 (1985).
7. Bush AI, Martins RN, Rumble B, Moir R, Fuller S, Milward E, et al. The amyloid precursor protein of Alzheimer's disease is released by human platelets. J Biol Chem 265: 15977-15983 (1990).
8. Borroni B, Perani D, Broli M, Colciaghi F, Garibotto V, Paghera B, et al. Pre-clinical diagnosis of Alzheimer disease combining platelet amyloid precursor protein ratio and rCBF spect analysis. J Neurol 252: 1359-1362 (2005).
9. Borroni B, Agosti C, Marcello E, Di Luca M, Padovani A. Blood cell markers in Alzheimer disease: amyloid precursor protein form ratio in platelets. Exp Gerontol 45: 53-56 (2010).
10. Inestrosa NC, Alarcon R, Arriagada J, Donoso A, Alvarez J. Platelet of Alzheimer patients: increased counts and subnormal uptake and accumulation of [14C] 5-hydroxytryptamine. Neurosci. Letter 163: 8-10 (1993).
11. Martin JF, Levine RP. Evidence in favor of the lungs and against the bone marrow as the site of platelet production. The Platelet in Health and Disease London Blackwell ScientificPage CP (1991).
12. Horstman LL, Jy W, Ahn YS, Zivadinov R, Maghzi AH, Etemadifar M, et al. Role of platelets in neuroinflammation: a wide-angle perspective. J Neuroinflammation. 7: 10 (2010).
13. Klinger MH. Platelets and inflammation. Anat Embryol (Berl). 196: 1-11 (1997).
14. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol. 58: 1985-1992 (2001).
15. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 34: 939-944 (1984).
16. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 12: 189-198 (1975).
17. Marksteiner J, Kemmler G, Weiss EM, Knaus G, Ullrich C, Humpel C, et al. Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 32: 539-540 (2011).
18. Fischer HP, Marksteiner J, Ransmayer G, Saria A, Humpel C. NGF but not GDNF or Neurturin anhanced acetylcoline tissue levels in striatal organotyoic brain slices. Int J Dev. Neurosci. 16: 391-401 (1998).
19. Ullrich C, Pirchl M, Humpel C. Hypercholesterolemia in rat impairs the cholinergic system and leads to memory deficits. Mol Cell Neurosci 45: 408-417 (2010).
20. Gibbins JM, Mahaut-Smith MP. Platelets and Megakaryocytes. Methods in molecular biology Volume 272 (1984).
21. Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 2009 54: 669-677 (2009).
22. Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F, et al. Microglial activation resulting from CD40-CD40L interaction after -amyloid stimulation. Science 286: 2353-2355 (1999).
23. Togo T, Akiyama H, Kondo H, Ikeda K, Kato M, Iseki E, et al. Expression of CD40 in the brain of Alzheimer's disease and other neurological diseases, Brain Res 885: 117-121 (2000).
24. Linder AF, Ni W, Diaz J, Szasz T, Burnett R, Watts SW. Serotonin (5-HT) in veins: not all in vain. J Pharmacol Exp 323: 415-425 (2007).
25. Soga F, Katoh N, Inoue T, Kishimoto S. Serotonin activates human monocytes and prevents apoptosis. J Invest Dermatol 127: 1947-1955 (2007).
26. Muck-Seler D, Presecki P, Mimica N, Mustapic M, Pivac N, Babic A, et al. Platelet serotonin concentration and monoamine oxidase type B activity in female patients in early, middle and late phase of Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 33: 1226-1231 (2009).
27. Di Luca M, Pastorino L, Bianchetti A, Perez J, Vignolo LA, Lenzi GL, et al. Differential level of platelet amyloid beta precursor protein isoforms: an early marker for Alzheimer disease. Arch Neurol 55: 1195-1200 (1998).
28. Galasko D, Montine TJ. Biomarkers of oxidative damage and inflammation in Alzheimer's disease. Biomark Med 4: 27-36 (2010).
29. Alvarez XA, Franco A, Fernandez-Novoa F, Cacabelos R. Blood levels of histamine, IL-1 beta and TNF-alpha in patients with mild to moderate Alzheimer disease. Mol Chem Neuropathol 29: 237-252 (1996).
30. Licastro F, Pedrini S, Caputo L, Annoni G, Davis LJ, Ferri C, et al. Increased plasma levels of interleukin-1, interleukin-6 and a-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? J Neuroimmunol 103: 97-102 (2000).
31. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13: 1359-1362 (2007).
32. Hawrylowicz CM, Howells GL, Feldmann M. Platelet-derived interleukin-1 induces human endothelial adhesion molecule expression and cytokine production. J Exp Med 174: 785-790 (1991).
33. Sedlmayr P, Blaschitz A, Wilders-Truschnig M, Tiran A, Dohr G. Platelets contain Interleukin-1 alpha and beta which are detectable on the cell surface after activation. Scand J Immunol 42: 209-214 (1995).
34. Lindemann S, Tolley ND, Dixon DA, McIntyre TM, Prescott SM, Zimmerman GA, et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol 154: 485-490 (2001).
35. Neben TY, Loebelenz J, Hayes L, McCarthy K, Stoudemire J, Schaub R, et al. Recombinant human interleukin-1 stimulates megakaryocytopoiesis and increases peripheral platelets in normal and splenectomized mice. Blood 81: 901-908 (1993).
36. Li L, Asteriou T, Bernert B, Heldin CH, Heldin P. Growth factor regulation of hyaluronan synthesis and degradation in human dermal fibroblasts: importance of hyaluronan for the mitogenic response of PDGF-BB. Biochem J 404: 327-336 (2007).
37. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79: 1283-1316 (1999).
38. Masliah E, Saitoh T. Lewy bodies, Alzheimer pathology and APP mutation. Neurosci Lett 180: 292-293 (1994).
39. Cohen S, Elliott GA. The stimulation of epidermal keratinization by a protein isolated from the submaxillary gland of the mouse. J Invest Dermatol 40: 1-5 (1963).
40. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem 265: 7709-7712 (1990).
41. Nagatsu T, Mogi M, Ichinose H, Togari A. Cytokines in Parkinson's disease. J Neural Transm Suppl 58: 143-151 (2000).
42. Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, et al. Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res 1333: 64-71 (2010).
43. Cielak D, Szulc-Kuberska J, Stepie H, Klimek A. Epidermal growth factor in human cerebrospinal fluid: reduced levels in amyotrophic lateral sclerosis. J Neurol 233: 376-377 (1986).
44. Chen-Plotkin AS, Hu WT, Siderowf A, Weintraub D, Goldmann Gross R, Hurtig HI. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol [Epub ahead of print] (2010).
45. Newman PJ. The biology of PECAM-1. J Clin Invest 100: 25-29 (1997).
46. Muller WA, Weigl SA, Deng X, Phillips DM. PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med 178: 449-460 (1993).
47. Chen M, Geng J. P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis. Arch Immunol Ther Exp 54: 75-84 (2006).
48. Merten M, Thiagarajan P. P-selectin expression on platelets determines size and stability of platelet aggregates. Circulation 102: 1931-1936 (2000).
49. Kozubski W, Swiderek M, Kloszewska I, Gwozdzinski K, Watala C. Blood platelet membrane fluidity and the exposition of membrane protein receptors in Alzheimer disease (AD) patients--preliminary Study. Alzheimer Disease and Associated Disordes 16: 52-54 (2002).
50. Hochstrasser T, Weiss E, Marksteiner J, Humpel C. Soluble cell adhesion molecules in monocytes of Alzheimer's disease and mild cognitive impairment. Exp Gerontology 45: 70-74 (2010).
51. Thornton P, McColl BW, Greenhalgh A, Denes A, Allan SM, Rothwell NJ. Platelet interleukin-1alpha drives cerebrovascular inflammation. Blood 115: 3632-3639 (2010).
52. Huo Y, Ley K. Adhesion molecules and atherogenesis. Acta Physiol Scand 173: 35-43 (2001).
53. Tousoulis D, Antoniades C, Nikolopoulou A, Koniari K, Vasiliadou C, Marinou K, et al. Interaction between cytokines and sCD40L in patients with stable and unstable coronary syndromes. Eur J Clin Invest 37: 623-628 (2007).
54. Casoli T, Di Stefano G, Balietti M, Solazzi M, Giorgetti B, Fattoretti P. Peripheral inflammatory biomarkers of Alzheimer's disease: the role of platelets. Biogerontology 11: 627-633 (2010).
55. Nielsen HM, Londos E, Minthon L, Janciauskiene SM. Soluble adhesion molecules and angiotensin-converting enzyme in dementia. Neurobiol Dis 26: 27-35 (2007).
56. Zuliani G, Cavalieri M, Galvani M, Passaro MR, Munari MR, Bosi C, et al. Markers of endothelial dysfunction on older subjetcs with late onset Alzheimer's disease or vascular dementia. J Neurol Science 272: 164-170 (2008).
57. Santos-Martínez MJ, Medina C, Jurasz P, Radomski MW. Role of metalloproteinases in platelet function. Thromb Res 121: 535-542 (2008).
58. Waubant E. Biomarkers indicitive of blood-brain barrier disruption in multiple sclerosis. Dis Markers 22: 235-244 (2006).
59. Lorenzl S, Albers DS, LeWitt PA. Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases. J Neurol Sci 207: 71-76 (2003).
60. Martín-Aragón S, Bermejo-Bescós P, Benedí J, Felici E, Gil P, Ribera JM, et al. Metalloproteinase's activity and oxidative stress in mild cognitive impairment and Alzheimer's disease. Neurochem Res 34: 373-378 (2009).
61. Mlekusch R, Humpel C. Matrix metalloproteinases-2 and-3 are reduced in cerebrospinal fluid with low beta-amyloid1-42 levels. Neurosci Lett 466: 135-158 (2009).
62. Rosenberg GA. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol 8: 205-216 (2009).
63. Fainardi E, Castellazzi M, Tamborino C, Trentini A, Manfrinato MC, Baldi E, et al. Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis. Mult Scler 15: 547-554 (2009).
64. Trysberg E, Blennow K, Zachrisson O, Tarkowski A. Intrathecal levels of matrix metalloproteinases in systemic lupus erythematosus with central nervous system engagement. Arthritis Res Ther 6: 551-556 (2004).
65. Lorenzl S, Albers DS, Narr S, Chirichigno J, Beal MF. Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson's disease. Exp Neurol 178: 13-20 (2002).
66. Amantea D, Russo R, Gliozzi M, Fratto V, Berliocchi L, Bagetta G, et al. Early upregulation of matrix metalloproteinases following reperfusion triggers neuroinflammatory mediators in brain ischemia in rat. Int Rev Neurobiol 82: 149-169 (2007).